5 Stocks Pulling The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.6%) at 15,838 as of Wednesday, Jan. 29, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 929 issues advancing vs. 2,026 declining with 145 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include GlaxoSmithKline ( GSK), down 1.9%, Sanofi ( SNY), down 1.3% and Novo Nordisk A/S ( NVO), down 1.1%. A company within the industry that increased today was Medivation ( MDVN), up 12.2%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.46 (-0.7%) to $63.63 on light volume. Thus far, 490,951 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $63.28-$63.79 after having opened the day at $63.39 as compared to the previous trading day's close of $64.09.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $80.1 billion and is part of the health care sector. The company has a P/E ratio of 12.8, below the S&P 500 P/E ratio of 17.7. Shares are up 8.0% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts that rate AstraZeneca a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

IPOs That Should Be on Your Radar

New Teva CEO Just Added Nearly 13% to Company's Market Cap Without Even Starting